Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October ... Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

Shire announces third quarter 2009 financial results News-Medical.net We have also continued to grow VYVANSE's market share which is now 13.4%, benefiting from both the 'back to school' season and strong 10% ADHD market growth ... and more »

Shire plc to Present Scientific Data on ADHD Treatments TransWorldNews (press release) The treatments being presented are INTUNIC (guanfacine) Extended Release Tablets, Vyvanse (lisdexamfetamine dimesylate) Capsules CII, and Daytrana ... Shire to Present Important Study Findings on its ADHD Treatments at a Major ... Reuters all 51 news articles »

Shire says ADHD patch works for adolescents Forbes AP , 10.30.09, 06:01 PM EDT NEW YORK -- Shire PLC says clinical studies show its attention deficit hyperactivity disorder patch Daytrana, which is approved ... Shire Reports Tolerability and Clinical Effects Results of Daytrana(R ... Reuters Market Report -- In Play (SHPGY) MSN Money Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting News-Medical.net RTT News  - istockAnalyst.com (press release) all 44 news articles »